Literature DB >> 11999625

Visual field and electrophysiological abnormalities due to vigabatrin.

Kors van der Torren1, Hellen S Graniewski-Wijnands, B C P Polak.   

Abstract

The purpose of this study was to determine the electrophysiological changes in patients using the anti epileptic drug vigabatrin and to correlate these findings with the previously reported risk for visual field loss in these patients. In 1998 the neurologists of both involved hospitals referred all patients on vigabatrin medication for ophthalmological examination to the outpatients clinics. Of the 33 patients whom were referred to our outpatient clinics, four had to be dropped from the study because of disability to perform the examinations the remaining 29 patients were included in the study. Standard ophthalmological investigations were carried out, and contrast sensitivity, visual field (Humphrey 30-2 and Esterman or Octopus 32), colour vision (panel D15), ERG and EOG according to ISCEV standards were tested. 18 patients continued the medication and 11 stopped taking the drug during the study. Nine of the patients who stopped the drug were followed during at least half a year afterwards, this group will be described in the combined article 'Electro ophthalmic recovery after withdrawal from vigabatrin' (Graniewski and Van der Torren, this issue). The electro-ophthalmological findings in the group of 29 patients were correlated with the visual fields and the daily and cumulative dosages of vigabatrin. Of the patients, 32% showed no visual field constriction at all; from these patients 64% had EOG and/or ERG changes. Of the patients with slight to marked visual field constriction, 90% presented EOG and/or ERG changes. Significant correlation between daily dosages of vigabatrin and visual field defects was shown as well as between visual field defects and rod and cone b wave amplitude reductions. Cumulative vigabatrin dosages presented a significant correlation with EOG ratio and ERG rod b-wave amplitude. Conclusively EOG and ERG testing were found to be even an more accurate way to monitor the direct vigabatrin effect on the outer retina and is possible different from the visual field testing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999625     DOI: 10.1023/a:1014615517996

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  13 in total

1.  Visual field defect associated with vigabatrin: observational cohort study.

Authors:  L V Wilton; M D Stephens; R D Mann
Journal:  BMJ       Date:  1999-10-30

2.  Different contributions of GABAA and GABAC receptors to rod and cone bipolar cells in a rat retinal slice preparation.

Authors:  T Euler; H Wässle
Journal:  J Neurophysiol       Date:  1998-03       Impact factor: 2.714

3.  Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.

Authors:  N Blackwell; J Hayllar; G Kelly
Journal:  BMJ       Date:  1997-06-07

4.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

5.  Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina.

Authors:  M J Neal; J R Cunningham; M A Shah; S Yazulla
Journal:  Neurosci Lett       Date:  1989-03-13       Impact factor: 3.046

6.  Outer retinal dysfunction in patients treated with vigabatrin.

Authors:  C F Arndt; P Derambure; S Defoort-Dhellemmes; J C Hache
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

Review 7.  Diversity of GABA receptors in the vertebrate outer retina.

Authors:  B A Mustafa
Journal:  Trends Neurosci       Date:  1995-03       Impact factor: 13.837

8.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

9.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

Authors:  H Daneshvar; L Racette; S G Coupland; P J Kertes; A Guberman; D Zackon
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

10.  The rabbit electroretinogram: effect of GABA and its antagonists.

Authors:  I Gottlob; L Wündsch; F K Tuppy
Journal:  Vision Res       Date:  1988       Impact factor: 1.886

View more
  13 in total

1.  The effect of GABA and the GABA-uptake-blocker NO-711 on the b-wave of the ERG and the responses of horizontal cells to light.

Authors:  Renate Hanitzsch; Lea Küppers; Andreas Flade
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

2.  mTOR Inhibition Mitigates Molecular and Biochemical Alterations of Vigabatrin-Induced Visual Field Toxicity in Mice.

Authors:  Kara R Vogel; Garrett R Ainslie; Michelle A Schmidt; Jonathan P Wisor; K Michael Gibson
Journal:  Pediatr Neurol       Date:  2016-10-03       Impact factor: 3.372

3.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

4.  Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.

Authors:  Dorothea Besch; Ulrich Schiefer; Nicole Eter; Roland Burth; Christian E Elger; Manfred Spitznas; Klaus Dietz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-05       Impact factor: 3.117

5.  Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy.

Authors:  John M Wild; Philip E M Smith; Carlo Knupp
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

6.  Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats.

Authors:  Firas Jammoul; Julie Dégardin; Dorothée Pain; Pauline Gondouin; Manuel Simonutti; Elisabeth Dubus; Romain Caplette; Stéphane Fouquet; Cheryl M Craft; José A Sahel; Serge Picaud
Journal:  Mol Cell Neurosci       Date:  2010-02-01       Impact factor: 4.314

Review 7.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.

Authors:  Carol A Westall; Rita Nobile; Sharon Morong; J Raymond Buncic; William J Logan; Carole M Panton
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

9.  Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication. Effect of vigabatrin in the rabbit eye.

Authors:  Ulrika Kjellström; Anitha Bruun; Fredrik Ghosh; Sten Andréasson; Vesna Ponjavic
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-03       Impact factor: 3.117

10.  Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.

Authors:  Ulrika Kjellström; Monica Lövestam-Adrian; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2008-01-10       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.